NIH Reporter #5R21CA267584-02

Research Project: Impact of Obesity on Immuno-Oncology Agents in Endometrial Cancer

This opportunity from the National Cancer Institute (NCI), part of the NIH, seeks research proposals to study the impact of obesity on immuno-oncology agents in endometrial cancer patients at the University of North Carolina at Chapel Hill. - Government Buyer: - National Cancer Institute (NCI), National Institutes of Health (NIH) - Research conducted at University of North Carolina at Chapel Hill - OEMs and Vendors: - Roche (manufacturer of atezolizumab) - Oncoceutics (manufacturer of ONC201) - Products/Services Requested: - Clinical research project evaluating atezolizumab and ONC201 in obese and non-obese endometrial cancer patients - Assessment of pharmacokinetics, pharmacodynamics, safety, tolerability, and biomarker responses - Expertise in immuno-oncology clinical research and biomarker analysis required - Unique/Notable Requirements: - Parallel cohort design (obese vs. non-obese) - Focus on biomarker analysis and drug response in endometrial cancer - Single research project, not a multi-year contract - Estimated contract value: $172,653 - Primary products: atezolizumab, ONC201 - Notable requirement for clinical research expertise in immuno-oncology agents

Description

This project aims to evaluate the impact of obesity on the pharmacokinetics and pharmacodynamics of immuno-oncology agents in endometrial cancer, focusing on the drugs atezolizumab and ONC201. The study involves parallel cohorts of obese and non-obese patients, assessing safety, tolerability, and biomarker responses. The research is conducted at UNC Chapel Hill under the National Cancer Institute (NCI), part of the NIH. The funding opportunity is active with a response deadline of August 26, 2024.

View original listing